Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL (REAL)
PI3K-Inhibitor Registry Study: Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
Sponsor: SecuraBio
Terminated
Strategy Change
Other terminated trials from SecuraBio
Other Chronic Lymphocytic Leukemia trials with similar outcome
A observational or N/A phase clinical study on Chronic Lymphocytic Leukemia and Follicular Lymphoma, this trial is terminated or withdrawn. The trial is conducted by SecuraBio and has accumulated 8 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Apr 2021 — Jul 2024 [monthly]
Terminated
Status: Recruiting → Terminated
-
Jan 2021 — Apr 2021 [monthly]
Recruiting
-
Aug 2020 — Jan 2021 [monthly]
Recruiting
▶ Show 3 earlier versions
-
Jul 2020 — Aug 2020 [monthly]
Recruiting
-
Jun 2020 — Jul 2020 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
May 2020 — Jun 2020 [monthly]
Not Yet Recruiting
First recorded
Apr 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- SecuraBio
For direct contact, visit the study record on ClinicalTrials.gov .